Equities research analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a note issued to investors on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.
Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Pulmatrix in a report on Tuesday, August 15th.
Pulmatrix Trading Down 1.1 %
Institutional Trading of Pulmatrix
Several hedge funds have recently made changes to their positions in PULM. Renaissance Technologies LLC grew its position in Pulmatrix by 7.3% during the second quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,300 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Pulmatrix in the 2nd quarter worth about $141,000. Mariner LLC purchased a new position in shares of Pulmatrix in the 4th quarter worth about $97,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Pulmatrix in the 1st quarter worth about $73,000. 11.62% of the stock is currently owned by institutional investors.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
- Five stocks we like better than Pulmatrix
- How to Buy Metaverse Stock Step by Step
- 3 value stocks you shouldn’t let go of this quarter
- How to Invest in Insurance Companies: A Guide
- 5 must-have next-gen technologies that institutions are buying
- Following Congress Stock Trades
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.